Inferra AIResearch Tools

Inferra AI / Company / AUPH

Aurinia Pharmaceuticals

AUPH · Health Care

Last earnings Oct 30, 2026

Key results

Revenueytd

$83.7 million

Financial Results Total Revenue For the three and nine months ended September 30, 2026, total revenue was $83.7 million and $244.6 million, up 14% and 19%, respectively, from $73.5 million and $205.9 million, respectively, in the same periods of 2025.

SEC original ↗Aurinia Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2026

RevenueQ3 2026

$244.6 million

Financial Results Total Revenue For the three and nine months ended September 30, 2026, total revenue was $83.7 million and $244.6 million, up 14% and 19%, respectively, from $73.5 million and $205.9 million, respectively, in the same periods of 2025.

SEC original ↗Aurinia Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2026

Growthquarter

up 14%

Financial Results Total Revenue For the three and nine months ended September 30, 2026, total revenue was $83.7 million and $244.6 million, up 14% and 19%, respectively, from $73.5 million and $205.9 million, respectively, in the same periods of 2025.

SEC original ↗Aurinia Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2026

License, Collaboration and Royalty Revenue For the three and nine months ended September 30, 2026, license, collaboration and royalty revenue was $4.3 million and $12.2 million, up 54% and 39%, respectively, from $2.8 million and $8.8 million, respectively, in the same periods of 2025.

SEC original ↗Aurinia Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2026

Net incomeytd

$38.7 million

Net Income For the three and nine months ended September 30, 2026, net income before taxes was $38.7 million and $131.4 million, up 21% and 67%, respectively, from $32.0 million and $78.5 million, respectively, in the same periods of 2025.

SEC original ↗Aurinia Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2026

Net incomeQ3 2026

$131.4 million

Net Income For the three and nine months ended September 30, 2026, net income before taxes was $38.7 million and $131.4 million, up 21% and 67%, respectively, from $32.0 million and $78.5 million, respectively, in the same periods of 2025.

SEC original ↗Aurinia Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2026

For the three and nine months ended September 30, 2026, net income was $31.7 million and $103.5 million, flat and up 35%, respectively, from $31.6 million and $76.4 million, respectively, in the same periods of 2025.

SEC original ↗Aurinia Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2026

EPSytd

$0.23

Diluted Earnings per Share For the three and nine months ended September 30, 2026, diluted earnings per share was $0.23 and $0.76, flat and up 38%, respectively, from $0.23 and $0.55, respectively, in the same periods of 2025.

SEC original ↗Aurinia Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2026

EPSQ3 2026

$0.76

Diluted Earnings per Share For the three and nine months ended September 30, 2026, diluted earnings per share was $0.23 and $0.76, flat and up 38%, respectively, from $0.23 and $0.55, respectively, in the same periods of 2025.

SEC original ↗Aurinia Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2026

AI analysis

Q3 2026 · reported Oct 30, 2026

Based on: Earnings release + parent 8-K — transcript not held

Revenue · Q3 2026
$244.6M
EX-99 · Oct 30, 2026
EPS · Q3 2026
$0.76
EX-99 · Oct 30, 2026
Net income · Q3 2026
$131.4M
EX-99 · Oct 30, 2026

The quarter in charts

Guidance ladder — revenue

Delivered vs the company's guided range

EX-99 · Oct 30, 2026 Guide as stated by the company; range and midpoint computed from the stated figure.

Headline figures

MetricQ3 2026Prior qtrYear ago
Revenue$244.6 million$83.2 million—
Growthup 14%up 19%—
Net income$131.4 million$37.4 million—
EPS$0.76$0.28—

EX-99 · Oct 30, 2026

Guidance · company-stated

Direction: Raised

Revenue$315 million

“2026 Total Revenue and Net Product Sales Guidance Aurinia is increasing its total revenue guidance for 2026 from a range of $315 million to $325 million to a range of $325 million to $330 million.”

Midpoint vs latest-quarter revenue+28.8%computed from stated figures

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

For the nine months ended September 30, 2026, cash outflows from financing activities were $53.2 million, which primarily included the repurchase of 5.0 million of the Company s common shares for $74.9 million, partially offset by proceeds from issuance of common shares for equity awards, net of tax withholding payments, of $35.9 million.

What changed vs last quarter

  • Guide midpoint vs latest-quarter revenue +28.8% computed from stated figures
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress EDMONTON, Alberta October 30, 2026 Aurinia Pharmaceuticals Inc

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “2026 Total Revenue and Net Product Sales Guidance Aurinia is increasing its total revenue guidance for 2026 from a range of $315 million to $325 million to a range of $325 million to $330 million.”

Revenue — Raised (“increasing”)
“2026 Total Revenue and Net Product Sales Guidance Aurinia is increasing its total revenue guidance for 2026 from a range of $315 million to $325 million to a range of $325 million to $330 million.”

Classified from the release's primary full-year outlook statement.

Capital allocation

For the nine months ended September 30, 2026, cash outflows from financing activities were $53.2 million, which primarily included the repurchase of 5.0 million of the Company s common shares for $74.9 million, partially offset by proceeds from issuance of common shares for equity awards, net of tax withholding payments, of $35.9 million.

SEC original ↗Aurinia Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2026

Strategy & priorities

About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs.

SEC original ↗Aurinia Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2026

Risks & headwinds

We caution investors that forward-looking statements are based on management s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect.

SEC original ↗Aurinia Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2026

These risks and uncertainties include, but are not limited to, those associated with LUPKYNIS net product sales, the timing of clinical study results and other risks and uncertainties identified in our filings with the U.

SEC original ↗Aurinia Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2026

Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia s most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators System for Electronic Document Analysis and Retrieval (SEDAR) website at www.

SEC original ↗Aurinia Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2026

What changed vs prior quarter

Guidance direction — prior quarter: Reiterated; this quarter: Raised

SEC original ↗Aurinia Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2026

Revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Aurinia Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2026

Net income — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Aurinia Pharmaceuticals — Earnings release (8-K exhibit)EX-99Oct 30, 2026

Documents

Earnings deck slides

7 decks with slide view

Aurinia Pharmaceuticals — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Aurinia Pharmaceuticals — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Slide history — recurring slides by stated title

Slides are matched across this company’s decks by their stated title only; a title listed here appeared in more than one held deck.

Aritinercept — Oct 29, 2026 · slide 3 · Oct 29, 2026 · slide 23 · Oct 30, 2026 · slide 23

2024 ACR LN Treatment Guideline Emphasizes Early and Aggressive — Oct 29, 2026 · slide 10 · Oct 30, 2026 · slide 10

2026 Financial Guidance — Oct 29, 2026 · slide 6 · Oct 30, 2026 · slide 6

Adverse Reactions Occurring in ≥3% of Patients Treated with — Oct 29, 2026 · slide 16 · Oct 30, 2026 · slide 16

Aritinercept Is a Dual BAFF/APRIL Inhibitor — Oct 29, 2026 · slide 24 · Oct 30, 2026 · slide 24

Aritinercept Is a High Affinity Dual BAFF/APRIL Inhibitor a — Oct 29, 2026 · slide 26 · Oct 30, 2026 · slide 26

Aritinercept Potently Inhibits BAFF- and APRIL-Mediated — Oct 29, 2026 · slide 27 · Oct 30, 2026 · slide 27

Aritinercept SAD Study: Safety Summary — Oct 29, 2026 · slide 29 · Oct 30, 2026 · slide 29

Aritinercept SAD Study: Single Doses of Aritinercept Led to Robust — Oct 29, 2026 · slide 30 · Oct 30, 2026 · slide 30

Aritinercept Single Ascending Dose (SAD) Study: Design — Oct 29, 2026 · slide 28 · Oct 30, 2026 · slide 28

Changing the — Oct 29, 2026 · slide 3 · Oct 30, 2026 · slide 3

Complementary Mechanisms May Work in Concert to Enhance Efficacy — Oct 29, 2026 · slide 19 · Oct 30, 2026 · slide 19

Corporate Presentation — Oct 29, 2026 · slide 1 · Oct 30, 2026 · slide 1

Effect of a Single Dose of BAFF/APRIL Inhibitors on IgA — Oct 29, 2026 · slide 31 · Oct 30, 2026 · slide 31

Effect of a Single Dose of BAFF/APRIL Inhibitors on IgG — Oct 29, 2026 · slide 33 · Oct 30, 2026 · slide 33

Effect of a Single Dose of BAFF/APRIL Inhibitors on IgM — Oct 29, 2026 · slide 32 · Oct 30, 2026 · slide 32

Forward — Oct 29, 2026 · slide 2 · Oct 29, 2026 · slide 2

Forward-Looking Statements — Oct 29, 2026 · slide 2 · Oct 30, 2026 · slide 2

LUPKYNIS Is a Novel, Structurally Modified CNI that Targets LN with — Oct 29, 2026 · slide 11 · Oct 30, 2026 · slide 11

LUPKYNIS Rapidly Reduced Proteinuria in Fewer Days in AURORA 1 a — Oct 29, 2026 · slide 14 · Oct 30, 2026 · slide 14

LUPKYNIS® — Oct 29, 2026 · slide 7 · Oct 30, 2026 · slide 7

Lupus Nephritis (LN) Is Among the Most Severe and Dangerous — Oct 29, 2026 · slide 8 · Oct 30, 2026 · slide 8

New Analysis (EULAR 2026) a Shows LUPKYNIS Associated with 53% — Oct 29, 2026 · slide 15 · Oct 30, 2026 · slide 15

PRESERVE Study Schema — Oct 29, 2026 · slide 22 · Oct 30, 2026 · slide 22

PRESERVE: — Oct 29, 2026 · slide 17 · Oct 30, 2026 · slide 17

Proteinuria Reduction Is Associated with Long-Term Renal Preservation — Oct 29, 2026 · slide 9 · Oct 30, 2026 · slide 9

Recent Financial — Oct 29, 2026 · slide 4 · Oct 30, 2026 · slide 4

Robust Clinical Study History — Oct 29, 2026 · slide 12 · Oct 30, 2026 · slide 12

Role of BAFF and APRIL — Oct 29, 2026 · slide 25 · Oct 30, 2026 · slide 25

Summary and Next Steps — Oct 29, 2026 · slide 34 · Oct 30, 2026 · slide 34

While LUPKYNIS Results Are the Strongest, the Majority of LN — Oct 29, 2026 · slide 18 · Oct 30, 2026 · slide 18

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

71 documents

Earnings releases

13 documents

Presentations

9 documents

Transcripts

0 documents

No transcripts for Aurinia Pharmaceuticals are held in this edition of the library.

See also the earnings calendar for every tracked company’s next earnings date.